Drug Shortage Report for JAMP-RISEDRONATE
Report ID | 137087 |
Drug Identification Number | 02368552 |
Brand name | JAMP-RISEDRONATE |
Common or Proper name | Risedronate |
Company Name | JAMP PHARMA CORPORATION |
Market Status | CANCELLED POST MARKET |
Active Ingredient(s) | RISEDRONATE SODIUM |
Strength(s) | 35MG |
Dosage form(s) | TABLET |
Route of administration | ORAL ORAL |
Packaging size | 4 |
ATC code | M05BA |
ATC description | DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION |
Reason for shortage | Other (Please describe in comments) |
Anticipated start date | |
Actual start date | 2019-11-01 |
Estimated end date | 2022-12-30 |
Actual end date | |
Shortage status | Actual shortage |
Updated date | 2021-04-07 |
Company comments | Supply Issues |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 1310 RUE NOBEL BOUCHERVILLE, QUEBEC CANADA J4B 5H3 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v2 | 2021-04-07 | French | Compare |
v1 | 2021-04-07 | English | Compare |
Showing 1 to 2 of 2